1. Home
  2. CAPT vs GTBP Comparison

CAPT vs GTBP Comparison

Compare CAPT & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CAPT

Captivision Inc.

N/A

Current Price

$0.41

Market Cap

13.2M

Sector

Finance

ML Signal

N/A

Logo GT Biopharma Inc.

GTBP

GT Biopharma Inc.

N/A

Current Price

$0.41

Market Cap

12.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CAPT
GTBP
Founded
2005
1965
Country
South Korea
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2M
12.1M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
CAPT
GTBP
Price
$0.41
$0.41
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
152.1K
783.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.75
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.30
$0.39
52 Week High
$1.93
$3.73

Technical Indicators

Market Signals
Indicator
CAPT
GTBP
Relative Strength Index (RSI) 42.71 33.33
Support Level $0.40 $0.41
Resistance Level $0.46 $0.78
Average True Range (ATR) 0.02 0.03
MACD 0.00 0.00
Stochastic Oscillator 34.18 20.10

Price Performance

Historical Comparison
CAPT
GTBP

About CAPT Captivision Inc.

Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.

About GTBP GT Biopharma Inc.

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

Share on Social Networks: